中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2014年
12期
909-912
,共4页
果宏峰%李宁忱%曹明%薛蔚%黄翼然%贺大林%张心如%谷宝军%那彦群
果宏峰%李寧忱%曹明%薛蔚%黃翼然%賀大林%張心如%穀寶軍%那彥群
과굉봉%리저침%조명%설위%황익연%하대림%장심여%곡보군%나언군
核基质相关蛋白质类%膀胱肿瘤%诊断%试剂盒,诊断%多中心研究
覈基質相關蛋白質類%膀胱腫瘤%診斷%試劑盒,診斷%多中心研究
핵기질상관단백질류%방광종류%진단%시제합,진단%다중심연구
Nuclear matrix-associated proteins%Urinary bladder neoplasms%Diagnosis%Reagent kits,diagnostic%Multicenter studies
目的 探讨尿核基质蛋白22(nuclear matrix protein 22,NMP22)检测在快速诊断膀胱癌中的临床价值. 方法 在全国4家三级医院泌尿外科选取803例患者和200例健康人的尿液标本,以NMP22检测试剂盒(胶体金法)快速检测NMP22水平.803例患者中膀胱癌组392例,其他泌尿系良性疾病/有非膀胱癌肿瘤史或患非膀胱部位的活动期癌症患者组411例.结合膀胱镜检和术后病理检查结果,统计分析NMP22检测的敏感性和特异性. 结果 1 003例受检者中NMP22检测膀胱癌的总体敏感性为69.6％(273/392,95％ CI 64.9％ ～ 74.0％),特异性为84.9％(519/611,95％ CI 81.1％～87.6％).337例膀胱癌患者获得病理分期结果,NMP22检测的敏感性分别为Ta～T1期69.6％(165/237)、T2～T4期82.0％ (82/100);322例获得病理分级结果,NMP22检测的敏感性分别为G1级60.5％(72/119)、G2级66.2％(47/71)、G3级90.9％ (120/132).NMP22检测对泌尿系良性疾病组、有非膀胱癌肿瘤史或患非膀胱部位的活动期癌症患者组、健康对照组的检测特异性分别为87.8％(324/369)、69.0％(29/42)和97.5％(195/200). 结论 NMP22试剂盒检测膀胱癌具有较高的敏感性和特异性,可用于早期、快速辅助诊断膀胱癌.
目的 探討尿覈基質蛋白22(nuclear matrix protein 22,NMP22)檢測在快速診斷膀胱癌中的臨床價值. 方法 在全國4傢三級醫院泌尿外科選取803例患者和200例健康人的尿液標本,以NMP22檢測試劑盒(膠體金法)快速檢測NMP22水平.803例患者中膀胱癌組392例,其他泌尿繫良性疾病/有非膀胱癌腫瘤史或患非膀胱部位的活動期癌癥患者組411例.結閤膀胱鏡檢和術後病理檢查結果,統計分析NMP22檢測的敏感性和特異性. 結果 1 003例受檢者中NMP22檢測膀胱癌的總體敏感性為69.6％(273/392,95％ CI 64.9％ ～ 74.0％),特異性為84.9％(519/611,95％ CI 81.1％～87.6％).337例膀胱癌患者穫得病理分期結果,NMP22檢測的敏感性分彆為Ta～T1期69.6％(165/237)、T2～T4期82.0％ (82/100);322例穫得病理分級結果,NMP22檢測的敏感性分彆為G1級60.5％(72/119)、G2級66.2％(47/71)、G3級90.9％ (120/132).NMP22檢測對泌尿繫良性疾病組、有非膀胱癌腫瘤史或患非膀胱部位的活動期癌癥患者組、健康對照組的檢測特異性分彆為87.8％(324/369)、69.0％(29/42)和97.5％(195/200). 結論 NMP22試劑盒檢測膀胱癌具有較高的敏感性和特異性,可用于早期、快速輔助診斷膀胱癌.
목적 탐토뇨핵기질단백22(nuclear matrix protein 22,NMP22)검측재쾌속진단방광암중적림상개치. 방법 재전국4가삼급의원비뇨외과선취803례환자화200례건강인적뇨액표본,이NMP22검측시제합(효체금법)쾌속검측NMP22수평.803례환자중방광암조392례,기타비뇨계량성질병/유비방광암종류사혹환비방광부위적활동기암증환자조411례.결합방광경검화술후병리검사결과,통계분석NMP22검측적민감성화특이성. 결과 1 003례수검자중NMP22검측방광암적총체민감성위69.6％(273/392,95％ CI 64.9％ ～ 74.0％),특이성위84.9％(519/611,95％ CI 81.1％～87.6％).337례방광암환자획득병리분기결과,NMP22검측적민감성분별위Ta～T1기69.6％(165/237)、T2～T4기82.0％ (82/100);322례획득병리분급결과,NMP22검측적민감성분별위G1급60.5％(72/119)、G2급66.2％(47/71)、G3급90.9％ (120/132).NMP22검측대비뇨계량성질병조、유비방광암종류사혹환비방광부위적활동기암증환자조、건강대조조적검측특이성분별위87.8％(324/369)、69.0％(29/42)화97.5％(195/200). 결론 NMP22시제합검측방광암구유교고적민감성화특이성,가용우조기、쾌속보조진단방광암.
Objective To evaluate the clinical significance of nuclear matrix protein 22 (NMP22) test in rapid diagnosis of bladder cancer.Methods From February 2009 to November 2011,803 patients and 200 healthy individuals were included in this multicenter study from four urology centers in China.They provided a urine sample for test of NMP22 protein using a point-of-care NMP22 BladderChek control kit (colloidal gold method).All tests were evaluated in a blinded fashion.Patients were divided into three groups.Group 1 included 392 patients of bladder cancer; group 2 included 411 patients who had benign urinary disease with non-bladder cancer history or non-bladder cancer; group 3 included 200 healthy individuals.The sensitivity and specificity of NMP22 test were analyzed compared with pathologic results using Pearson Chi-square test.Results The overall sensitivity and specificity of the NMP22 test were 69.6％ (273/392,95％ CI 64.9％-74.0％) and 84.9％ (519/611,95％CI 81.1％-87.6％),respectively.In group 1,337 patients had pathologic stage data,and the sensitivities of the NMP22 test for each stage were Ta-T1 69.6％ (165/237) and T2-T4 82.0％ (82/100),respectively; 322 patients had pathologic grade data,and the sensitivities for each grade were G1 60.5％ (72/119),G2 66.2％ (47/71) and G3 90.9％ (120/132),respectively.The specificities for patients of benign urinary disease,of non-bladder cancer history or nonbladder cancer and healthy individuals were 87.8％ (324/369),69.0％ (29/42) and 97.5％ (195/200),respectively.Conclusion NMP22 BladderChek control kit had high sensitivity and specificity in detection of bladder cancer,and it can be used in early detection and rapid diagnosis of bladder cancer.
